ArticleAntimicrobial agents and chemotherapy2015
Macrolide-resistant Mycoplasma pneumoniae in adults in Zhejiang, China.
Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 85 citations in OpenAlex.
- Immunochromatography for the diagnosis of Mycoplasma pneumoniae infection: A systematic review and meta-analysis.PloS one · 2020Pooled it
- A2063G macrolide-resistant Mycoplasma pneumoniae: epidemic dominance without more frequent pulmonary consolidation or worse short-term in-hospital outcomes in hospitalized children.BMC pediatrics · 2026Article
- Prevalence of Macrolide-resistant Mycoplasma pneumoniae in Children and Adolescents With Community-acquired Pneumonia: A Prospective Study in Thailand.The Pediatric infectious disease journal · 2026Article
- Article
- Article
- Comparing differences in onset and clinical manifestations between children and adults withFrontiers in public health · 2026Article
- AgeFrontiers in pediatrics · 2026Article
- Evolution and characteristics of tetracycline resistance inMicrobiology spectrum · 2025Article
- Macrolide resistance inFrontiers in cellular and infection microbiology · 2025Article
- Antimicrobial susceptibility and molecular characteristics ofFrontiers in pediatrics · 2025Article
- Macrolide-resistantHeliyon · 2024Article
- Efficacy and Influencing Factors of Sangju Cough Mixture in the Adjuvant Treatment of Adult Patients withInfection and drug resistance · 2024Article
- The Clinical Significance of Pathogen Loads and Macrolide Resistance Levels for Macrolide-ResistantJournal of inflammation research · 2024Article
- Influence of non-pharmaceutical interventions on epidemiological characteristics ofFrontiers in microbiology · 2024Article
- A Novel Detection Procedure for Mutations in the 23S rRNA Gene of Macrolide-ResistantMicroorganisms · 2023Article
- Novel mechanisms of macrolide resistance revealed byFrontiers in cellular and infection microbiology · 2023Article
- The clinical significance of macrolide resistance in pediatricFrontiers in cellular and infection microbiology · 2023Article
- Severe problem of macrolides resistance to common pathogens in China.Frontiers in cellular and infection microbiology · 2023Review
- Molecular beacon based real-time PCR p1 gene genotyping, macrolide resistance mutation detection and clinical characteristics analysis of Mycoplasma pneumoniae infections in children.BMC infectious diseases · 2022Article
- RefractoryJournal of clinical medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycoplasma pneumoniae is a major pathogen causing community-acquired pneumoniae (CAP), which is generally treated with macrolides. In recent years, however, although macrolide-resistant M. pneumoniae has been reported frequently, particularly in China, very little is known about the prevalence of macrolide-resistant M. pneumoniae infection in adults. In this study, we survey the macrolide-resistant M. pneumoniae in adults in Zhejiang province and characterize the mechanisms of resistance to macrolide. Six hundred fifty throat swab samples were collected from adult patients with CAP from January 2012 to August 2014. These samples were assayed by nested PCR and then cultivated for M. pneumoniae. All isolates were sequenced to determine the mutation in domain V of the 23S rRNA gene. The activities of 10 antibiotics against macrolide-resistant M. pneumoniae isolates were also investigated in vitro. Moreover, restriction fragment length polymorphism (RFLP) analysis of the amplified P1 gene was used to type 50 resistant strains. One hundred percent (71/71) of M. pneumoniae strains isolated from adults with CAP were resistant to erythromycin (MIC=128 to >256 μg/ml), clarithromycin (MIC=128 to >256 μg/ml), and azithromycin (MIC=32 to >64 μg/ml). Furthermore, all macrolide-resistant M. pneumoniae strains identified had an A2063G mutation in domain V of the 23S rRNA gene. Forty-six resistant strains (92.0%) were classified into type I strain on the basis of P1 gene PCR-RFLP analysis. According to these findings, it is suggested that macrolide-resistant M. pneumoniae infection is very prevalence among adults in Zhejiang province. Thus, there is necessary to perform the epidemiological monitoring of macrolide-resistant M. pneumoniae in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.